Farmakoterapia w Psychiatrii i Neurologii
eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Standardy etyczne i procedury Recenzenci Zasady publikacji prac
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

without publication fees

Otwarty dostęp

without publication fees
2/2025
vol. 41
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
Artykuł przeglądowy

Zespół z odstawienia, zespół dyskontynuacji i efekt z odbicia związane ze stosowaniem wybranych grup leków

Barbara Sobera
1
,
Mateusz Gadzała
1
,
Przemysław Mikołajczak
2
,
Dagmara Mirowska-Guzel
3

  1. Department of Clinical and Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland; Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej, Centrum Badań Przedklinicznych, Warszawski Uniwersytet Medyczny, Warszawa
  2. Department of Pharmacology, Poznań University of Medical Sciences, Poznań, Poland; Katedra i Zakład Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań
  3. Neurological Clinic, Institute of Psychiatry and Neurology, Warsaw; Poradnia Neurologiczna, Instytut Psychiatrii i Neurologii, Warszawa
Farmakoterapia w Psychiatrii i Neurologii 2025
DOI: https://doi.org/10.5114/fpn.2025.159504
Data publikacji online: 2026/04/28
Plik artykułu:
- Withdrawal syndrome, discontinuation syndrome and rebound effect in the treatment with selected drug  [0.59 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Ashton H. Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat 1991; 8: 19-28.
2. Athavale A, Murnion B. Gabapentinoids: a therapeutic review. Aust Prescr 2023; 46: 80-85.
3. Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA et al. Benzodiazepine dependence: focus on withdrawal syndrome. Ann Pharm Fr 2009; 67: 408-13.
4. Barbera J, Shapiro C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 2005; 28: 301-18.
5. Barbosa Eyler GE, Utria Castro JV. Zolpidem dependence and withdrawal. A case report of generalized seizures. Rev Colomb Psiquiatr (Engl Ed) 2023; 52: 265-267.
6. Berridge V, Mars S. History of addictions. J Epidemiol Community Health 2004; 58: 747-50.
7. Blackman G, Oloyede E. Clozapine discontinuation withdrawal symptoms in schizophrenia. Ther Adv Psychopharmacol 2021; 11: 20451253211032053.
8. Cerovecki A, Musil R, Klimke A, Seemuller F, Haen E, Schennach R et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 2013; 27: 545-72.
9. Chen G, Lai S, Bao G, Ke J, Meng X, Lu S et al. Distinct reward processing by subregions of the nucleus accumbens. Cell Rep 2023; 42: 112069.
10. Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M et al. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy. Psychother Psychosom 2017; 86: 189-219.
11. Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-Induced Tardive Dyskinesia: A Review and Update. Ochsner J 2017; 17: 162-174.
12. Cosci F. Withdrawal symptoms after discontinuation of a noradrenergic and specific serotonergic antidepressant: A case report and review of the literature. Personalized Medicine in Psychiatry 2017; 1–2: 81-84.
13. Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychother Psychosom 2020; 89: 283-306.
14. Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev 2015; 2015: CD009652.
15. De La Iglesia-Larrad JI, Barral C, Casado-Espada NM, De Alarcon R, Macia-Casas A, Vicente Hernandez B et al. Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: A review of the literature. Psychiatry Res 2020; 284: 112660.
16. De Las Cuevas C, Sanz E, De La Fuente J. Benzodiazepines: more "behavioural" addiction than dependence. Psychopharmacology (Berl) 2003; 167: 297-303.
17. Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006; CD005194.
18. Divljakovic J, Milic M, Timic T, Savic MM. Tolerance liability of diazepam is dependent on the dose used for protracted treatment. Pharmacol Rep 2012; 64: 1116-25.
19. Driot D, Chicoulaa B, Jouanjus E, Dupouy J, Oustric S, Lapeyre-Mestre M. Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. Therapie 2016; 71: 575-578.
20. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychother Psychosom 2015; 84: 72-81.
21. Fluyau D, Hashmi MF, Charlton TE 2025. Drug Addiction. StatPearls. Treasure Island (FL).
22. Gabriel M, Sharma V. Antidepressant discontinuation syndrome. CMAJ 2017; 189: E747.
23. Gahr M, Schonfeldt-Lecuona C, Kolle MA, Freudenmann RW. Withdrawal and discontinuation phenomena associated with tranylcypromine: a systematic review. Pharmacopsychiatry 2013; 46: 123-9.
24. Gardner EL. Addiction and brain reward and antireward pathways. Adv Psychosom Med 2011; 30: 22-60.
25. Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol 2013; 9: 155-62.
26. Gunther M, Valido A, Jiang S, Stern TA. Antihistamines: Indications, Interactions, and Adverse Effects. Prim Care Companion CNS Disord 2025; 27: 25f03958.
27. Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant Withdrawal and Rebound Phenomena. Dtsch Arztebl Int 2019; 116: 355-361.
28. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms - Authors' reply. Lancet Psychiatry 2019; 6: 562-563.
29. Horowitz MA, Framer A, Hengartner MP, Sorensen A, Taylor D. Estimating Risk of Antidepressant Withdrawal from a Review of Published Data. CNS Drugs 2023; 37: 143-157.
30. Howland RH. Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv 2010; 48: 9-12.
31. Ishikawa H, Takeshima M, Ishikawa H, Ayabe N, Ohta H, Mishima K. Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review. Neuropsychopharmacol Rep 2021; 41: 434-439.
32. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 2016; 3: 760-773.
33. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 2002; 1: 13-20.
34. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348: 1786-95.
35. Kosten TR, Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. Am J Addict 2019; 28: 55-62.
36. Lader M, Kyriacou A. Withdrawing Benzodiazepines in Patients With Anxiety Disorders. Curr Psychiatry Rep 2016; 18: 8.
37. Lagisetty P, Garpestad C, Larkin A, Macleod C, Antoku D, Slat S et al. Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse. Drug Alcohol Depend 2021; 221: 108583.
38. Lander M, Bastiampillai T, Sareen J. Review of withdrawal catatonia: what does this reveal about clozapine? Transl Psychiatry 2018; 8: 139.
39. Lewis RG, Florio E, Punzo D, Borrelli E. The Brain's Reward System in Health and Disease. Adv Exp Med Biol 2021; 1344: 57-69.
40. Lieberman J. Cholinergic rebound in neuroleptic withdrawal syndromes. Psychosomatics 1981; 22: 253-4.
41. Madsen, Marianne M, M S. Psychological dependence. EBSCO Research Starters 2024.
42. Mathieson S, Lin CC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. BMJ 2020; 369: m1315.
43. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271-80.
44. Nathan PE, Conrad M, Skinstad AH. History of the Concept of Addiction. Annu Rev Clin Psychol 2016; 12: 29-51.
45. O'Brien C. Addiction and dependence in DSM-V. Addiction 2011; 106: 866-7.
46. Olmedo R, Hoffman RS. Withdrawal syndromes. Emerg Med Clin North Am 2000; 18: 273-88.
47. Olver J, Burrows G, Norman T. Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors. CNS Drugs 1999; 171-177.
48. Otani K, Tanaka O, Kaneko S, Ishida M, Yasui N, Fukushima Y. Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol 1994; 9: 131-3.
49. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006; 67 Suppl 4: 27-30.
50. Schjerning O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J. Abuse Potential of Pregabalin: A Systematic Review. CNS Drugs 2016; 30: 9-25.
51. Siwek M, Chrobak AA, Gorostowicz A, Krupa AJ, Dudek D. Withdrawal Symptoms Following Discontinuation of Vortioxetine-Retrospective Chart Review. Pharmaceuticals (Basel) 2021; 14: 451.
52. Soyka M. Treatment of Benzodiazepine Dependence. N Engl J Med 2017; 376: 2399-2400.
53. Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet 2020; 395: 1938-1948.
54. Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 2012; 73: 1002-8.
55. Stepnicki P, Kondej M, Kaczor AA. Current Concepts and Treatments of Schizophrenia. Molecules 2018; 23: 2087.
56. Szalavitz M, Rigg KK, Wakeman SE. Drug dependence is not addiction-and it matters. Ann Med 2021; 53: 1989-1992.
57. Tallarida RJ. Receptor discrimination and control of agonist-antagonist binding. Am J Physiol 1995; 269: E379-91.
58. Tan KR, Brown M, Labouebe G, Yvon C, Creton C, Fritschy JM et al. Neural bases for addictive properties of benzodiazepines. Nature 2010; 463: 769-74.
59. Teixeira MZ. Rebound effect of modern drugs: serious adverse event unknown by health professionals. Rev Assoc Med Bras (1992) 2013; 59: 629-38.
60. Theilman SB, Christenbury MM. Hypomania following withdrawal of trazodone. Am J Psychiatry 1986; 143: 1482-3.
61. Torres-Lockhart KE, Lu TY, Weimer MB, Stein MR, Cunningham CO. Clinical Management of Opioid Withdrawal. Addiction 2022; 117: 2540-2550.
62. Van Leeuwen E, Van Driel ML, Horowitz MA, Kendrick T, Donald M, De Sutter AI et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev 2021; 4: CD013495.
63. Verghese C, Deleon J, Nair C, Simpson GM. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 1996; 39: 135-8.
64. Volkow ND, Michaelides M, Baler R. The Neuroscience of Drug Reward and Addiction. Physiol Rev 2019; 99: 2115-2140.
65. Wang HY, Chou WJ, Huang TY, Hung CF. Acute dystonia resulting from abrupt bupropion discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 766-8.
66. Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. Neurol Ther 2018; 7: 233-248.
67. Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. Am Fam Physician 2006; 74: 449-56.
68. Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol 2015; 5: 357-68.
69. Wislowska-Stanek A, Jarkiewicz M, Mirowska-Guzel D. Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders. Pharmacol Rep 2025; 77: 303-314.
70. Xie F, Liu B, Yang L, Huang J, Li B, Li Y. Zolpidem-related euphoria, addiction and detoxification: A case report and review of the literature. Medicine (Baltimore) 2024; 103: e40280.
71. Yee B, Looi JCL, Agaciak M, Allison S, Chan SKW, Bastiampillai T. Non-Psychosis Symptoms of Clozapine Withdrawal: a Systematic Review. East Asian Arch Psychiatry 2023; 33: 44-64.

Termedia
O Wydawnictwie Oferty Newsletter Kontakt Praca
Polityka prywatności Polityka reklamowa Napisz do nas Nota prawna Regulamin
Na skróty
Aktualności Czasopisma Książki eBooki Konferencje i webinary Podcasty Mednauka
Serwisy
KONGRES TOP MEDICAL TRENDS Menedżer Zdrowia Lekarz POZ Choroby rzadkie Dermatologia Diabetologia Onkologia Neurologia Reumatologia Gastroenterologia Pulmonologia Ginekologia Kurier Medyczny Zalecenia i rekomendacje e-Praktyka Leczenia Ran Warto wiedzieć Biblioteka podcastów
e-Akademia
e-Akademia Zaburzeń Mikrobioty e-Akademia POChP e-Akademia Chorób Naczyń
© 2026 Termedia Sp. z o.o.
Developed by Termedia.